Denmark’s New Strategy for Personalised Medicine
Denmark’s New Strategy for Personalised Medicine

insight

Denmark's New Strategy for Personalised Medicine

insight

Denmark's New Strategy for Personalised Medicine

In August 2025, Denmark took another decisive step towards the future of personalised medicine and precision healthcare. With a third national strategy for personalised medicine for 2025-2027, backed by DKK 90 million over three years, Denmark is doubling down on its ambition to stay at the global forefront of personalised and data-driven healthcare. 

When

Why Denmark is elevating personalised medicine

Personalised medicine is evolving rapidly and, supported by the previous two strategies, Denmark now holds a strong position in this field, particularly within genome sequencing and analysis. With the new Strategy for Personalised Medicine, The Danish Government and the Danish Regions set the direction for how to further advance this area through an enhanced focus on the full patient journey, shared decision-making between stakeholders and increased support of the entire ecosystem. 

Building on a solid foundation of research, health data, and public-private partnerships, the strategy aims to make personalised medicine an integrated part of the Danish healthcare system. The third strategy reinforces Denmark’s strong position in the life science sector, strengthening the country’s competitiveness and resilience, and positioning Denmark as a global frontrunner in personalised and data-driven healthcare. 
The strategy outlines seven priority areas, including: 

  1. Putting patients first
  2. Strengthening the foundation for research and innovation 
  3. Positioning Denmark as an international frontrunner in advanced therapies and data-driven healthcare
  4. Increasing efficiency and enhance quality across the healthcare system
  5. Enhancing biobanks and health data infrastructure
  6. Leveraging the potential of AI and health data
  7. Expanding personalised medicine across the healthcare sector

In short: Denmark is building a healthcare system designed for precision, powered by data, and open for partnership.

 

A new definition of personalised medicine

  • Genetic information
  • Biomarkers
  •  Health data
  • New technologies and artificial intelligence 
  • Lifestyle factors
  • Patient needs and preferences 
 

Concrete Initiatives

At its core, the strategy seeks to put the patient first and ensure that prevention, diagnosis, and treatment are tailored to each individual. To realise this vision a number of concrete initiatives have been launched, including efforts to:

  • Support the establishment of a National Centre for User Collaboration

  • Develop a code of conduct for patient involvement in personalised medicine to strengthen inclusion and trust

  • Promote the development and implementation of advanced therapies (ATMPs) within academic environments

  • Explore opportunities to enhance early disease detection through the use of health data

  • Strengthen Danish biobanks to support research and innovation

  • Map current practices and assess the value creation of citizen-generated health data

  • Support the development of pharmacogenetic analysis methods

  • Examine the possibilities and challenges of establishing a national pharmacogenetic profile

  • Reduce side effects through a more individualised approach to drug selection and dosing

  • Establish variant and frequency databases to ensure more consistent and efficient use of genetic knowledge

  • Improve patient treatment through the effective use of genomic data

A strategic moment for companies developing advanced therapies and digital health solutions

One of the standout elements of the strategy is the strong national commitment to Advanced Therapy Medicinal Products (ATMPs). Denmark already stands out globally for its uniquely integrated environment where researchers, clinicians and companies work side by side, supported by trusted public-private collaborations models and world-leading, linkable health data.

Add to that Denmark’s comprehensive biobank infrastructure and a regulatory culture designed for innovation rather than limitation, and you get a country where ATMP development can move from idea to implementation faster and more predictably.

For companies working with AI-enabled diagnostics, predictive modelling or personalised treatment pathways, the strategy is equally good news. Denmark’s ambition is to make the full potential of health data available in a secure, ethical and innovation-friendly way, giving business the testbed, they need to scale solutions across real healthcare environments.

Denmark’s proposition: A small country with a global health impact

By combining strong political commitment with world-class research, clinical excellence and a uniquely integrated data ecosystem, Denmark continues to strengthen its position as one of Europe’s most competitive life science hubs.

For international investors and innovators, that means access to:

- A predictable regulatory environment

- Unparalleled health data quality

- Rapid clinical validation opportunities

- A collaborative culture where bold ideas can be tested, refined and scaled

Denmark may be small in size, but it is big on personalised medicine.

“With this new Strategy Denmark is taking Personalised Medicine to the next level. With an increased focus on using new innovative health technologies supported by better access to Denmark's unique health data and biobanks, the mission is to develop more targeted treatments across the entire healthcare system” 

Lea Milling Korsholm

PhD and Special Advisor, Invest in Denmark

Lea Milling Korsholm - Special Advisor - Life Sciences - Invest in Denmark

Get in touch

Explore opportunities in Denmark’s personalised-medicine ecosystem

If you are developing data-driven healthcare solutions, advanced therapies or AI-powered diagnostics, Denmark offers a uniquely fertile environment to innovate, collaborate and scale.

Connect with Invest in Denmark to explore partnership opportunities, identify ideal research or business locations, or learn how your organisation can benefit from Denmark’s ambitious national strategy for personalised medicine.

Copenhagen

  • Sarina Lohmann

    Title: Special Advisor – Maritime and transport – Analysis & Partnerships

    Area: Copenhagen

    Phone: +4533920423

Berlin

Kolding

Silkeborg

Aarhus

Aalborg

Oslo

London

Paris

Munich

New-York

Toronto

Silicon-Valley

Tokyo

Bangalore

Taipei

Shanghai

Singapore